Prostate Cancer and Prostatic Diseases

Article	Citations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging	112
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?	98
Concerns regarding prostate cancer screening guidelines in minority populations	93
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction	73
New BPH therapy classification: what really FITs?	67
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study	62
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?	55
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis	52
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	50
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer	49
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes	43
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions	43
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study	42
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)	39
Best of 2022 in prostate cancer and prostatic diseases	37
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis	36
Sexual outcomes in men who have sex with men who underwent radical prostatectomy	35
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer	35
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations	35
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro	35
Incidence of prostate cancer in transgender women in the US: a large database analysis	34
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer	34
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study	32
Missing the full picture: Pathology, anatomy, and operator effects in HoLEP comparisons	32
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients	32

Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms	32
Feasibility and safety study of the Flostent™ system (RAPID-I)	32
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure	31
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts	31
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study	31
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy	30
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer	30
TRexit is going one step further	30
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer	30
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions	29
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer	28
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	28
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database	26
The evolving clinical use of prostate cancer biomarkers	26
The effects of glycemic index on prostate cancer progression in a xenograft mouse model	25
Reply to RE: Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?	25
Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort	24
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	24
Antimicrobial prophylaxis: To do or not to do? This is the question	23
The times have changed. Let the urologists change!	23
“Targeted microwave ablation: another way to kick the can(cer) down the road?”	23
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction	22
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study	22
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials	22
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision	21
Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system	21
High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate	21
Methodological concerns regarding KEYNOTE-199: immortal time bias and treatment attribution challenges in combination immunotherapy	21
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT	21
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy	21
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants	21
Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics	21
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	20
Editorial Expression of Concern: Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells	20
Survivorship in prostate cancer following robotic assisted radical prostatectomy–the time to act is now!	20
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	20
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK	20
Prognostic value of MR visibility/invisibility in men on Active Surveillance	20
Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer	20
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies	20
Association of prostate cancer with human papillomavirus infections: a case-control study	20
Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	19
A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer	19
Established focal therapy—HIFU, IRE, or cryotherapy—where are we now?—a systematic review and meta-analysis	19
Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey	19
The role of preoperative prostatic shape in the recovery of urinary continence after robotic radical prostatectomy: a single cohort analysis	19
The relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy	18
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan	18
Re: Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	18
Sleep disturbances are underappreciated in prostate cancer survivorship	18

Perioperative outcomes comparing the DaVinci 5 with DaVinci Xi in patients undergoing robotic-assisted radical prostatectomy	18
Revisiting ADT in mCRPC: balancing oncologic control and mitochondrial implications	17
Risk calculators for the detection of prostate cancer: a systematic review	17
Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores	17
Top-down holmium laser enucleation of the prostate (HoLEP) versus traditional HoLEP for the treatment of benign prostatic hyperplasia (BPH): 1-year outcomes of a randomized controlled trial	17
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer	17
Less is more: the “Safety Net Approach” balances precision and safety	17
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients—towards a tumor volume-based risk stratification	17
Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	16
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy	16
Cardiovascular risk in ADT recipients: does the type of ADT matter?	16
Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis	16
The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review	16
Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI	16
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study	15
Response to correspondence regarding “The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study”	15
Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?	15
MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis	15
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials	15
Practical management of hematuria after endoscopic surgery for benign prostatic obstruction	15
Characteristics of incidental prostate cancer in the United States	15
Prevalence and determinants of shared decision-making for PSA testing in the United States	15
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer	15
The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis	15
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey	15
5 T versus 3 T MRI for prostate cancer: an intra-individual prospective comparison of image quality and diagnostic performance	14
Negative perceptions of the health system and racial inequities in PSA screening	14
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	14
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer	13
The changing face of castrate resistant prostate cancer	13
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review	13
The impact of race on survival in metastatic prostate cancer: a systematic literature review	13
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings	13
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	13
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?	13
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	13
Biopsy strategies in the era of mpMRI: a comprehensive review	12
Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis	12
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomiz	12
Bridging the gap between PSMA-PET and reality: critical missing elements in AR-guided pelvic lymph node dissection	12
Best of 2023 in Prostate Cancer and Prostatic Diseases	12
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting	12
Quality of information and appropriateness of ChatGPT outputs for urology patients	12
Hyperglycemia and microRNAs in prostate cancer	12
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	12
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations	12
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with doceta	12
Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study	11
Overcoming barriers to prostate cancer genetic testing: who, when, and how	11
MISTs for benign prostatic hyperplasia as first line interventional treatment: Alea iacta est?	11
The value of micro-ultrasound for prostate cancer screening: A retrospective real-world feasibility study	11
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration	11
Quality of information and appropriateness of Open AI outputs for prostate cancer	11
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer	11
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients	11
Fecal incontinence after prostate cancer irradiation: a systematic literature review	11
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)	11
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis	11
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer	11
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis	11
Surveillance after Focal Therapy – a Comprehensive Review	11
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?	11
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry	11
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH	11
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	11
Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancer	10
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis	10
Best of 2024 in Prostate Cancer and Prostatic diseases	10
Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS	10
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer	10
Social determinants of health into evaluations of quality and appropriateness of AI assistant ChatGPT	10
Whack-a-met: serial SABR for repeated oligoprogression in metastatic CRPC	10
Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer	10
MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in i	10
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment	10
15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer	10
Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	10
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer	10
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care	10
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study	9

Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis	9
Re: Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP	9
Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis	9
AI-aided diagnostic performance for prostate MRI: systematic review and meta-analysis	9
Augmented Reality PSMA-3D guided robotic pelvic lymph node dissection (PLND) in prostate cancer patients	9
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	9
The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016	9
Quality of information and appropriateness of ChatGPT outputs for urology patients	9
Concerns regarding the methodological limitations of the OASIS study	9
Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis	9
Characterisation of cell lines derived from prostate cancer patients with localised disease	9
Targeted and perilesional biopsy: triumphs and cautions	9
New robotic platforms for prostate surgery: the future is now	9
Likelihood of sampling prostate cancer at systematic biopsy as a function of gland volume and number of cores	9
Relative search popularity of five advanced prostate cancer medications using Google Trends	9
Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study	9
Impact of transperitoneal anterior, retzius-sparing, extraperitoneal, transvesical and perineal approaches on urinary continence recovery after robot-assisted radical prostatectomy: a systematic revie	9
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer	9
Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis	8
Comparative analysis of robot-assisted simple prostatectomy: the HUGO™ RAS system versus the DaVinci® Xi system	8
Racial variation in the advanced prostate cancer genome	8
Does biodegradable peri-rectal spacer mitigate treatment toxicities in radiation therapy for localised prostate cancer—a systematic review and meta-analysis	8
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis	8
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab	8
Integrating clinical and technological perspectives to enhance predictive modeling in prostate cancer surgery	8
Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis	8
A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer	8
Prostate cancer screening in Europe: future directions and perspectives	8
Letter: The Hawthorne effect—behavioral changes from research observation—as confounder and mediator in the ERASE trial	8
Role of targeted biopsy, perilesional biopsy, random biopsy, and their combination in the detection of clinically significant prostate cancer by mpMRI/transrectal ultrasonography fusion biopsy in conf	8
Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes	8
Transperineal laser ablation in the management of benign prostatic hyperplasia: an updated systematic review and pooled analysis	8
Thulium fiber laser versus holmium MOSESTM laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: a randomized prospective clinical study	7
Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia	7
Artificial intelligence applications in prostate cancer	7
Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies	7
Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors	7
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates	7
Prostate cancer in New York City: impact of neighborhood level social determinants of care	7
Short term results after minimally invasive treatments for benign prostatic enlargement: the first randomized trial comparing transperineal laser ablation and water vapor ablation	7
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men	7
A Visual Standardized (ViSta) map integrating imaging (MRI), biopsy findings and Specimen Prostate Cancer location	7
Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis	7
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy	7
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board	7
Impact of peritoneal reconfiguration on lymphocele formation after robot-assisted radical prostatectomy with pelvic lymph node dissection: a systematic review and meta-analysis of randomized controlle	7
Advancing the treatment of localized prostate cancer with MR-guided radiotherapy	7
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine	7
The times they are (still) a-Changin’	7
Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients	7
Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis	6
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes	6
Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis	6
Letter to the editor: “Incidence of prostate cancer in transgender women in the US: a large database analysis.”	6
Urinary microbiota and prostatic diseases: the key for the lock? A systematic review	6
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or	6
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data	6
Benign prostatic hyperplasia during active surveillance for prostate cancer: is it time to define management strategies?	6
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial	6
Comparison of senhance and da vinci robotic radical prostatectomy: short-term outcomes, learning curve, and cost analysis	6
A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading	6
Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages—dependence on GPR120	6
Mitochondrial dysfunction in urologic disease	6
Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer	6
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)	6
Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany	6
Primary bladder neck obstruction in men—new perspectives in physiopathology	6
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide	6
Salvage treatments after focal therapy for prostate cancer – a comprehensive review	6
Head-to-head comparison of DaVinci and Hugo™ RAS robotic platforms for robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies	6
Setting new standards: robot-assisted radical prostatectomy as a day case	6
Publisher Correction: Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer	6
Editorial: Advancing external beam radiotherapy—and rediscovering what brachytherapy already provides?	6
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer	6
Perspective transition from transrectal to transperineal MRI-fusion biopsy under local anesthesia – the institutional TREXIT learning curve of the new gold standard	6
Infection risks and biopsy-associated complications in prostate cancer diagnosis: a review of recent literatures	6
Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies	6
Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark	6
Multiparametric prostate MRI improves the diagnosis of a clinically significant prostate cancer in PSA screening; but what is the benefit of additional risk calculators?	5
High level expression of glucocorticoid receptor (GR) is linked to aggressive tumor features, early biochemical recurrence, and genetic instability in prostate cancer	5
Resource use in the last year of life of prostate cancer patients—A register-based analysis	5
Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of c	5
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study	5
Relationship between cigarette use and prostate cancer risk: what do we know and what should we do?	5
External validation of an algorithm to personalize nerve sparing approaches during robot-assisted radical prostatectomy in men with unilateral high-risk prostate cancer	5
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis	5
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis “PCAN-23-0763R”	5
“Re: Should systematic prostatic biopsies be discontinued?”	5
From association to action: strengthening research on social determinants of health	5
Body composition as a determinant of the therapeutic index with androgen signaling inhibition	5
Fatty acid diet and prostate cancer: a treasure hunt or a wild goose chase?	5
The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort	5
Disparities in prostate cancer diagnosis and management: recognizing that disparities exist at all junctures along the prostate cancer journey	5
Genomic classifiers and prognosis of localized prostate cancer: a systematic review	5
Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer	5